



Machino Plastics Limited

Registered Office & Plant:

3, Maruti J.V. Complex, Delhi-Gurugram Road, Tel: 0124-2341218, 2340806
Haryana – 122015, India.

CIN: L25209HR2003PLC035034

Email: sec.legal@machino.com

Website: www.machino.com

The BSE Ltd.

Date: 01st June, 2026

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001
corp.relations@bseindia.com
Scrip Code No: 523248

Subject: Submission of Newspaper Publication under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 47 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith the copies of the Audited Financial Results for the quarter and year ended on 31st March, 2026 which were duly approved in the meeting of the Board of Directors held on 30th May, 2026, and published in the Business Standard newspaper on 01st June, 2026.

This information will also be available on the website of the Company at <https://machino.com>

Kindly take the same on record.

Thanking You

Yours Faithfully,
For Machino Plastics Limited

ADITYA Digitally signed by
JINDAL ADITYA JINDAL
Date: 2026.06.01
09:48:11 +05'30'



Aditya Jindal
Chairman cum Managing Director

MACHINO PLASTICS LTD.					
Regd. Office: Plot # 3, Maruti Joint Venture Complex, Delhi Gurugram Road, Gurugram, Haryana - 122015					
Phone: 9124-284128, 284088, Fax: 9124-284128, E-mail: info@machino.com, Website: www.machino.com					
CIN: L25200HR2005PL000504					
Extract of Statement of Unaudited Audited Financial Results for the Quarter / Year Ended 31 st March 2026					
Sl. No.	Particulars	Quarter ended		Year ended	
		31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25
(Rs. in Lakhs)					
Unaudited Audited Unaudited					
1.	Total Revenue from Operations (net)	14,346.08	42,612.62	14,346.08	14,346.08
2.	Net Profit / (Loss) before tax	24.24	263.03	292.68	292.68
3.	Net Profit / (Loss) after tax and exceptional items	26.91	32.28	269.47	269.47
4.	Total Comprehensive Income (after tax)	7,232.58	7,329.04	7,329.04	7,329.04
5.	Paid-up Equity Share Capital (face value of Rs. 10/- each)	613.68	613.68	613.68	613.68
6.	Reserves excluding revaluation surplus as per balance sheet of previous accounting year	-	4,506.31	-	-
7.	Earnings per share (EPS) after Extraordinary Items	0.41	2.16	5.71	5.71
8.	Basic EPS (Rs.)	0.41	2.16	5.71	5.71
9.	Diluted EPS (Rs.)	0.41	2.16	5.71	5.71
10.	Earnings per share (EPS) after Extraordinary Items	0.41	2.16	5.71	5.71
11.	Basic EPS (Rs.)	0.41	2.16	5.71	5.71
12.	Diluted EPS (Rs.)	0.41	2.16	5.71	5.71
Reserve excluding revaluation surplus for the period ended on 31 st March 2025 was Rs. 4,506.31 Lakhs.					
NOTES:					
1. The above unaudited/audited financial results for the quarter and year ended 31 st March, 2026 were reviewed by the audit committee and were taken on record by the Board of Directors in their meeting held on 30 th May, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.					
2. The above is an extract of the detailed format of unaudited/audited results for the quarter and year ended 31 st March, 2026, filed with SEBI under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements), 2015. The full format of the unaudited results for the quarter and audited results for the year ended 31 st March, 2026 are available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.machino.com).					
3. The above is an extract of the detailed format of unaudited/audited results for the quarter and year ended 31 st March, 2026, filed with SEBI under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements), 2015. The full format of the unaudited results for the quarter and audited results for the year ended 31 st March, 2026 are available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.machino.com).					
By Order of the Board For MACHINO PLASTICS LIMITED Sd/- Chairman cum Managing Director					
Place: Chandigarh Date: 30 th May, 2026					

OSWAL OVERSEAS LIMITED						
CIN No. : L74809NL1984PL001268						
Regd. Office: 98A, Second Floor, Nandwari Estate, Taimoor Nagar, New Delhi 110055						
Phone No. : 011-41984253, Fax No. : 011-26322884, E-mail: : cs@oswaloverseas.com, Website: : www.oswaloverseas.com						
EXTRACT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31.03.2026						
(Rs. in Lakhs)						
Sl. No.	Particulars	Quarter ended on	Quarter ended on	Quarter ended on	Year ended on	Year ended on
		31.03.2026	31.03.2025	31.12.2025	31.03.2026	31.03.2025
Audited Audited Unaudited Audited Audited						
1.	Total income from operations (net)	221.06	2870.55	115.44	400.91	8762.63
2.	Net Profit / (Loss) from ordinary activities after tax (before Extraordinary Items)	-266.52	-210.09	-191.87	-319.74	-1239.20
3.	Net Profit / (Loss) for the period after tax (after Extraordinary Items)	-265.71	-209.92	-191.87	-319.99	-1238.43
4.	Other Comprehensive Income	2.30	0.45	-0.01	4.97	2.15
5.	Net Profit/ Loss	-263.41	-209.43	-191.88	-312.03	-1236.24
6.	Equity Share Capital	646.11	646.11	646.11	646.11	646.11
7.	No. of Equity Shares of Rs. 5/- each	129.22	129.22	129.22	129.22	129.22
8.	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet)	-	-	-	-421.55	-329.57
9.	Earnings Per Share (after extraordinary items) (face value of Rs. 10/- each)	-	-	-	-	-
Basic :		-2.19	-1.62	-1.48	-7.06	-9.57
Diluted :		-2.19	-1.62	-1.48	-7.06	-9.57
Notes:						
1. The above is an extract of the detailed format of quarterly financial results filed with the stock exchanges under regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015. The full format of the quarterly and yearly financial results is available on the website of OSWAL Overseas Limited and the website of the company (www.oswaloverseas.com).						
2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30 th May, 2026.						
3. Sugar industry is a seasonal industry where crushing normally takes place during the period between November and April, while sales are distributed throughout the year. The performance of the company varies from quarter to quarter.						
4. Pursuant to the provisions of section 195BA of Income Tax Act 1961, as amended by the Taxation Laws (Amendment) Ordinance 2014 and promulgated as the Taxation Laws (Amendment) Act, 2016 enacted on 11 th December, 2019 with effect from 1 st April, 2019, domestic companies have an option to pay income tax at the concessional rate by foregoing certain exemptions / deductions (the 'new tax regime') as specified in the said section.						
Based on the assessment of the possible impact of the new tax regime, the Company has elected to continue with existing tax structure till certain deductions are available and accumulated Minimum Alternate Tax (MAT) credit is substantially exhausted and thereafter to opt for new tax regime as stated above.						
						
For Oswal Overseas Limited Sd/- Paramjeet Singh (Managing Director)						
CIN: 3031335						
Place : New Delhi Date : 30.05.2026						

NecLife		NECTAR LIFESCIENCES LIMITED			
Regd.Office: Shop No. 5, SL Enclave, Behind Sohi HP Gas Agency, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab 140507, Tel. + 91-0172-5078200, 5001687, Email: cs@nectarlifesciences.com, Website : www.nectarlifesciences.com, CIN: L21000PB1995PL016654					
Extract of Audited Financial Results for the Quarter and the year ended 31.03.2026 (₹ in Lakhs unless stated otherwise)					
Sl. No.	Particulars	Standalone		Consolidated	
		Quarter Ended	Year Ended	Quarter Ended	Year Ended
31-03-2026 31-03-2025 31-03-2026 31-03-2026 31-03-2026 31-03-2026					
1	Total income from continuing operations	128.97	0.63	201.05	128.97
2	Net Profit/(Loss), before Tax and before Extraordinary Items from continuing operations	(5,691.96)	(16.31)	(8,786.99)	(5,692.86)
3	Net Profit/(Loss), before Tax after Extraordinary Items from continuing operations	(5,691.96)	(16.31)	(8,786.99)	(5,692.86)
4	Net Profit/(Loss), before Tax and after Extraordinary Items from continuing operations	(3,720.60)	(10.60)	(5,734.11)	(3,721.22)
5	Net Profit/(Loss), before Tax and before Extraordinary Items from discontinued operations	(7,320.58)	(18,750.17)	(5,736.51)	(7,320.58)
6	Net Profit/(Loss), before Tax after Extraordinary Items from discontinued operations	-	-	16,337.32	-
7	Net Profit/(Loss), after Tax and after Extraordinary Items from discontinued operations	(3,071.20)	(12,998.30)	(22,554.37)	(3,071.20)
8	Total Profit/(Loss) for the period from continuing and discontinued operations	(6,791.80)	(13,008.90)	(29,288.48)	(6,792.42)
9	Other Comprehensive Income	7.92	53.98	7.92	53.98
10	Total Comprehensive Income (after tax)	(6,783.88)	(12,954.92)	(29,280.56)	(6,784.49)
11	Paid up Share Capital (face value of ₹1/- each)	1,942.61	2,242.61	1,942.61	2,242.61
12	Other Equity excluding Revaluation Reserve as per the Audited Balance Sheet	56,288.19	93,368.74	56,288.19	93,368.74
13	No. of weighted average shares (in Numbers)	20,092,737	22,42,60,370	20,092,737	22,42,60,370
14	Earnings per Share (face value of ₹1/- each)				
a. Basic - Continuing operations	(1.85)	-	(2.85)	(1.85)	-
b. Diluted - Continuing operations	(1.85)	-	(2.85)	(1.85)	-
c. Basic - Discontinued operations	(1.53)	(5.80)	(11.72)	(1.53)	(5.80)
d. Diluted - Discontinued operations	(1.53)	(5.80)	(11.72)	(1.53)	(5.80)
e. Basic - Continuing and Discontinued operations	(3.38)	(5.80)	(14.58)	(3.38)	(5.80)
f. Diluted - Continuing and Discontinued operations	(3.38)	(5.80)	(14.58)	(3.38)	(5.80)
Note 1. The above is an extract of the detailed format of Quarterly and Year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The full format of the financial results (including standalone results) are available on the Company's website at https://www.nectarlifesciences.com/about-us which can also be downloaded by scanning the QR code given below and on the website of the Stock Exchanges at www.bseindia.com and www.nseindia.com . The Board of Directors hereby declare that audit reports does not have any modified opinion. 2. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.					
Date: 30-05-2026 Place: Chandigarh				By Order of the Board of Directors of Nectar Lifesciences Limited (Sanjay Goyal) Chairman & Managing Director	

ADC India Communications Ltd.					
CIN: L3220KA1989PL000313					
Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058					
Tel: +91 80 2839 6102 / 2839 6291					
E-mail: support@adcl.com Website: www.adcl.com					
NOTICE TO SHAREHOLDERS					
SECOND 100-DAY CAMPAIGN - "SAKSHAM NIVESHAK"					
In continuation of the earlier 100-Day Campaign - "Saksham Niveshak" and pursuant to Investor Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs (MCA) directive on March 27, 2026, the Company has initiated the Second 100-Day Campaign - "Saksham Niveshak" from April 01, 2026 to July 09, 2026 for shareholders whose dividends remain undivided, with an emphasis on Know Your Customer (KYC) updation and related compliance measures. This notice is being issued by the Company as part of the aforesaid campaign.					
Shareholders who have not claimed their dividends for any of the financial years from FY 2018-19 (Final Dividend) to FY 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account mandates, Nominee registration and contact information (email, mobile number, postal address) or have any issues/queries related to undivided dividend and shares may write to the Company's Registrar and Transfer Agent (RTA), KFin Technologies Limited (Unit: ADC India Communications Limited), Selenium Tower B, Plot No. 31/32, Financial District, Nanakramguda, Hyderabad-500032. Email: einwardr@kfinetech.com; Toll Free No. 1800 409 4001.					
Shareholders may note that as per the provisions of the Companies Act, 2013, the undivided dividend for the financial year 2018-19 (Final Dividend) and corresponding shares are due for transfer to IEPFA on September 04, 2026. Shareholders may further note that this campaign has been initiated specifically to reach out to the shareholders to update their KYC details. The shareholders are requested to update their KYC details with the Company's RTA and claim their undivided dividends to prevent their shares being transferred to the IEPFA.					
Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim the undivided Dividends.					
For ADC India Communications Ltd Geetha Desikachari Company Secretary					
Place: Bangalore Date: June 1, 2026					

GUJARAT STATE FERTILIZERS & CHEMICALS LIMITED					
Fertilizer Road, 391 750, Vadodra, Gujarat					
CIN : L19999GJ1962PL001121 • www.gsfclimited.com					
Phone : 0265-3939354 • Fax : 0265-2240021 • E-mail Id: sec@gsfcltd.com					
NOTICE TO SHAREHOLDERS					
TRANSFER OF EQUITY SHARES TO INVESTOR EDUCATION & PROTECTION FUND (IEPFA) AUTHORITY					
Notice is hereby given that the Company would be transferring all those equity shares on which dividends have remained unpaid or undivided for seven consecutive years to IEPFA Account established by the Central Government pursuant to Section 124(b) of the Companies Act, 2013 ("Act") read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Amendment Rules, 2016 ("Rules"), as amended from time to time.					
The Company has sent letters to the concerned shareholders by Speed Post vide letter dated 20 th May, 2025 who have not claimed their dividend for last seven consecutive years from Financial Years 2018-19 to 2024-25, which are liable to be transferred to IEPFA Authority Account as per the said Rules. Those shareholders are requested to forward the required documents as mentioned in the said Letter to the Company.					
A list of such shareholders who have not encashed their dividends for seven consecutive years and whose shares are liable for transfer to the IEPFA Authority Account is available on Company's website at the web link https://gsfclimited.com/transfer-of-share-to-iefp .					
In the event the Company does not receive valid claim from the concerned Shareholder(s) by 31/08/2026 or such other date as may be specified, the Company shall, with a view to comply with the requirement set out in the Act and Rules, transfer the shares to the IEPFA Authority without any further notice in the following manner:-					
Physical Form: The original share certificates which are registered in the name of the shareholders will be cancelled and in lieu thereof, new share certificates will be issued and transferred in favour of the IEPFA.					
Dematerialised Form: The Company shall transfer the shares by way of corporate action through the respective depositories (NSDL or CDSL) to the IEPFA.					
The Shareholder(s) may note that both the undivided dividend amount(s) and the quantity shares transferred to the IEPFA including all benefits accruing on shares, if any, can be claimed by submitting the physical copy of the required documents to the Company for obtaining an Endorsement Letter. Once the Endorsement Letter is issued, thereafter shareholder(s) is/are required to file web-based Form IEPF-5 online on the website https://iefp.gov.in or https://gsfclimited.com/transfer-of-share-to-iefp along with the Endorsement Letter and send the physical copy of the same to the Company.					
Further, as per various circulars issued by NSDL, Shareholders whose Ledger Folios are not mapped with PAN, I.D. Number details and Bank Account details are requested to compulsorily furnish the details to the RTA for registering the same with respective Folios.					
For any information/queries on this matter, concerned Shareholders are requested to write to or contact to Company Secretary, GSFCL Limited, Fertilizer Road, 391750, Dist. Vadodra, Gujarat. Tel: No. 0265-3939354. Email: sec@gsfcltd.com or Company's Registrar and Share Transfer Agent, MUGF Intime India Private Limited, Unit : GSFCL Limited, "Goetankur", 1. Bhakti Nagar Colony, Behind ASD Towers, Old Padra Road, Vadodra - 390 015 Tel: 0265-356768.					
For Gujarat State Fertilizers & Chemicals Limited Sd/- Nidhi Pillai Place : Vadodra Date : 25-05-2026 Company Secretary & Vice President (Legal)					

NOTICE AND JOINT ADVERTISEMENT FOR THE MEETING OF EQUITY SHAREHOLDERS, SECURED CREDITORS AND UNSECURED CREDITORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

FORM NO. CAA-2

(PURSUANT TO SECTION 230(3) AND RULE 8 AND 7 OF COMPANIES (COMPROMISES, ARRANGEMENTS AND AMALGAMATIONS) RULES 2016)
BEFORE THE NATIONAL COMPANY LAW TRIBUNAL, CHENNAI BENCH-I

AND

IN THE MATTER OF SECTIONS 230 TO 232 OF THE COMPANIES ACT, 2013 AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT, 2013 READ WITH COMPANIES (COMPROMISES, ARRANGEMENTS AND AMALGAMATIONS) RULES, 2016

AND

IN THE MATTER OF SCHEME OF AMALGAMATION

AMONGST

DR. AGARWAL'S EYE HOSPITAL LIMITED (APPLICANT COMPANY NO.1/ TRANSFEROR COMPANY)

AND

DR. AGARWAL'S HEALTH CARE LIMITED (APPLICANT COMPANY NO.2/ TRANSFEREE COMPANY)

THEIR RESPECTIVE SHAREHOLDERS AND CREDITORS COMPANY APPLICATION (CAA) NO. 19/HC/2026

AND

DR. AGARWAL'S EYE HOSPITAL LIMITED
(CIN: L85110TN1994PL0027366)

A Company registered under the Companies Act of 1956.
Having its registered office at 6th Floor, Monon Elements, 1st Main Road,
Aurfin Nagar, Aurangabad, Chennai Tamil Nadu, India. 500 018.
Represented by Mrs. Meenakshi Jayaram, Company Secretary and Compliance Officer

Applciant Company No.1/ Transferor Company
The Hon'ble National Company Law Tribunal

Notice is hereby given that pursuant to the order dated May 05, 2026 of **Members of the Equity Shareholders, Secured Creditors and Unsecured Creditors of Dr. Agarwal's Eye Hospital Limited** (hereinafter called as **"Meetings"**) to be held for the purpose of considering, and thought fit, approving with or without modification, the Scheme of Amalgamation amongst, Dr. Agarwal's Eye Hospital Limited (Applicant Company No. 1/ Transferor Company) and Dr. Agarwal's Health Care Limited (Applicant Company No. 2/ Transferor Company) and their respective shareholders and creditors (**"Scheme"**) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Act").

Pursuant to the Order and in accordance with the directions contained therein, further notice is hereby given that the Meetings will be convened and held as under:

Date of Meeting		July 02, 2026		
Sr. No.	Name of the Company	Class of Meeting	Mode and Venue of Meeting	Time (IS)
1.	Dr. Agarwal's Eye Hospital Limited (Applicant Company No. 1/ Transferor Company)	Equity Shareholders (Secured Creditors)	Through Physical Mode The Music Academy, T.TA. Road, Chennai - 600 014.	09:00 AM 11:30 AM

The notice, together with the documents accompanying the same, of the Meetings has been sent to the Equity Shareholders of the Transferor Company whose names appear in the register of members, list of beneficial owners maintained by the depositor, Transferor Company, as mentioned below, Secured Creditors and Unsecured Creditors whose names are appearing in the records of the Transferor Company, as mentioned below:

Particulars of Meeting	Records date for Dispatch of Notice	Mode of Dispatch
Equity Shareholders of the Transferor Company	May 22, 2026	(i) Through electronic mode to the Equity Shareholders, Secured Creditors and Unsecured Creditors whose e-mail addresses are registered with NSDL/CDSL or available with the Transferor Company as per the recent record date, and
Secured Creditors of the Transferor Company	December 31, 2025	(ii) Through hard copy, providing the web -link and Quick response code accessing the Notice and related documents hosted on the website of the Company, to those whose e-mail addresses are not registered or available.

Copies of the Scheme, the statement under Sections 230 and 232 read with Section 102 of the Act and Rule 5 of the CAA Rules, and related documents are available on the website of the Transferor Company at <https://dragarwal.com/in/dr-agarwal-eyes-hospital/ind-convened-meeting-documents>, as well as on the websites of BSE Limited and NSDL. Physical copies may also be obtained free of cost by writing to investor@dragarwal.com. Alternatively, the documents can also be accessed by scanning the given QR code:



Persons entitled to attend and vote at the meeting of the Equity Shareholders, Secured Creditors and Unsecured Creditors of the Transferor Company may cast their votes through remote e-voting prior to the meeting or through polling paper voting at the meeting, in accordance with the instructions contained in the Notice. Such persons may attend and vote either in person through proxy or authorized representative, as applicable, provided that the fully completed proxy forms and authorization letters deposited at the registered registered office of the Transferor Company or emailed to corporate@dragarwal.com at least 48 hours before the meeting. Attendees are requested to bring the duly signed attendance slip annexed to the Notice.

Equity Shareholders, Secured Creditors and Unsecured Creditors who have not voted through remote e-voting may vote electronically at the meeting in the manner provided in the Notice, whereas those who have already voted through remote e-voting may attend meeting and shall not vote again. Only Equity Shareholders whose names appear in the register of members of beneficial owners as on the cut-off date shall be entitled to attend and vote at the meeting, and their voting rights shall be proportionate to the paid-up equity share capital of the Transferor Company as on such date. Voting rights of the Creditors shall be proportionate to debt due to them as on the cut-off date. Furthermore, equity shareholders and creditors are requested to carefully read the details of the scheme of amalgamation and the terms and conditions of the Transferor Company.

The Hon'ble NCLT has appointed Sri Kamraj Jai Arora as the Chairperson and Sri Shram Aravind V as the Scrutinizer of the aforesaid meetings of the Transferor Company. The above-mentioned Scheme, if approved in the Meetings, will be subject to subsequent approval of the Hon'ble NCLT and such approvals, permissions and sanctions of regulatory or other authorities, as may be necessary and other conditions prescribed as contemplated in the Scheme.

The cut-off date for voting (including remote e-voting, voting through polling papers and e-voting during the meeting) and time period for casting of the votes shall be as under:

MACHINO PLASTICS LTD.				
Regd. Office: Plot # 3, Maruti Joint Venture Complex, Delhi Gurugram Road, Gurugram, Haryana - 122015 Phone: 011-2617812466, Fax: 011-2617812467, Email: info@machino.com, Website: www.machino.com CIN: L25209HR2003PLC003534				
Extract of Audited Financial Results for the Quarter Year Ended 31st March 2026				
Sl. No.	Particulars	(Rs. in Lakhs)		
		Quarter ended 31-Mar-26	Year ended 31-Mar-26	Quarter ended 31-Mar-25
		(Unaudited)	(Audited)	(Unaudited)
1	Total Revenue from Operations (net)	14,58.89	42,91.62	16,71.91
2	Net Profit/(Loss) before tax	34.24	263.63	262.98
3	Net Profit/(Loss) after tax & exceptional items	25.61	193.28	282.47
4	Total Comprehensive Income (after tax)	7,232.60	7,339.84	308.26
5	Paid-up Equity Share Capital (face value of Rs. 10/- each)	613.68	613.68	613.68
6	Reserves excluding revaluation surplus as per balance sheet of previous accounting year	-	4,326.31	-
7	Earnings per share (EPS) after Exceptional items (a) Basic EPS (Rs.) (b) Diluted EPS (Rs.) (face value of Rs. 10/- each)	0.41	2.16	5.71
8	Earnings per share (EPS) after Exceptional items (a) Basic EPS (Rs.) (b) Diluted EPS (Rs.) (face value of Rs. 10/- each)	0.41	2.16	5.71
9	Reserve excluding revaluation surplus for the period ended as on 31st March 2025 was Rs. 4,751.94 lakhs.			

NOTES:

1. The above unaudited/audited financial results for the quarter and year ended 31st March, 2026 were reviewed by the audit committee and were taken on record by the Board of Directors in their meeting held on 30th May, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.

2. The above is an extract of the detailed format of unaudited/audited results for the quarter and year ended 31st March, 2026, filed with Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter and audited results for the year ended 31st March, 2026 are available on the Stock Exchange website (www.sebiindia.com) and on the Company's website (www.machino.com).

3. Reserve excluding revaluation surplus for the period ended as on 31st March 2025 was Rs. 4,751.94 lakhs.

By Order of the Board
For MACHINO PLASTICS LIMITED
Sd/-
Aditya Jindal
Chairman cum Managing Director

Place: Gurugram
Date: 30th May, 2026

ADC INDIA Communications Ltd.
CIN: L32209KA1888PLC009313
Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058
Tel: +91 80 2839 6102 / 2839 6291
E-mail: support@adccom.com Website: www.adccom.com

**NOTICE TO SHAREHOLDERS
SECOND 100-DAY CAMPAIGN - "SAKSHAM NIVESHAK"**

In continuation of the earlier 100-Day Campaign - "Saksham Niveshak" and pursuant to Investor Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs (MCA) directive on March 27, 2026, the Company has initiated the Second 100-Day Campaign - "Saksham Niveshak" from April 01, 2026 to July 09, 2026 for shareholders whose dividends remain unclaimed, with an emphasis on Know Your Customer (KYC) updation and related compliance measures. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years for FY 2018-19 (Final Dividend) to FY 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account mandates, Nominee registration and contact information (email, mobile number, postal address) or have any issues/queries related to unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA), KFin Technologies Limited (Unit: ADC India Communications Limited), Selenium Tower B, Plot No. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: emward.rts@kfin.tech, Toll Free No. 1800-409-4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unclaimed dividends for the financial years 2018-19 (Final Dividend) and corresponding shares are due for transfer to IEPFA on September 04, 2026. Shareholders may further note that this campaign has been initiated specifically to reach out to the shareholders to update their KYC details. The shareholders are requested to update their KYC details with the Company's RTA and claim their unclaimed dividends to prevent their shares being transferred to the IEPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim the unclaimed Dividends.

For ADC India Communications Ltd
Geetha Desikachari
Company Secretary
Place: Bangalore
Date: June 1, 2026

GUJARAT STATE FERTILIZERS & CHEMICALS LIMITED
Fertilizers, Chemicals, 391 750, Vadodra, Gujarat, India
CIN: L19999GJ1962PLC01121 • www.gsfclimited.com
Phone: 0265-393854 • Fax: 0265-244021 • Email: sec@gsfcltd.com

**NOTICE TO SHAREHOLDERS
TRANSFER OF EQUITY SHARES TO INVESTOR EDUCATION & PROTECTION FUND (IEPFA) AUTHORITY**

Notice is hereby given that the Company would be transferring all those equity shares on which dividends have remained unpaid or unclaimed for seven consecutive years to IEPFA Account established by the Central Government pursuant to Section 124(6) of the Companies Act, 2013 ("Act") read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Amendment Rules, 2016 ("Rules"), as amended from time to time.

The Company has sent Letters to the concerned shareholders by Speed Post vide dated 20th May, 2026 who have not claimed their dividend for last seven consecutive years from Financial Years 2018-19 to 2024-25, which are liable to be transferred to IEPFA Authority Account as per the said Rules. Those shareholders are requested to forward the required documents as mentioned in the said Letter to the Company.

A list of such shareholders who have not encashed their dividends for seven consecutive years and whose shares are liable for transfer to the IEPFA Authority is available on Company's website at the web link <https://gsfclimited.com/transfer-of-shares-to-iefp>.

In the event the Company does not receive valid claim from the concerned Shareholder(s) by 31-08-2026 or such other date as may be specified, the Company shall, with a view to comply with the requirement set out in the Act and Rules, transfer the shares to the IEPFA Authority without any further notice in the following manner:-

Physical Form: The original share certificates which are registered in the name of the shareholders will be cancelled and in lieu thereof, new share certificates will be issued and transferred in favour of the IEPFA.

Dematerialised Form: The Company shall transfer the shares by way of corporate action through the respective Depositories (NSDL or CDSL) to the IEPFA.

The Shareholder(s) may note that both the unclaimed dividend amount(s) and the quantity shares transferred to the IEPFA including all benefits accruing on shares, if any can be claimed by submitting the physical copy of the required documents to the Company for obtaining an Entitlement Letter. Once the Entitlement is issued, thereafter shareholder is required to file web-based Form IEPF-S online on the website www.iepf.gov.in or <https://gsfclimited.com/transfer-of-shares-to-iefp> along with the Entitlement Letter and send the physical copy of the same to the Company.

Further, as per various circulars issued by SEBI, Shareholders whose Ledger Folios are not mapped with PAN, Email ID, Nomination details and Bank Account details are requested to promptly furnish the details to the RTA for registering the same with respective FoC(s).

For any information/discussions on this matter, concerned Shareholders are requested to write or contact to Company Secretary, GSFCL Limited, Fertilizer-guar-391750, Dist. Vadodra, Gujarat Tel: 0265-393854. Email: sec@gsfcltd.com or Company's Registrar and Share Transfer Agent, MUGF Intime India Private Limited, Unit : GSFCL Limited, "Geetanjali", 1, Bhakti Nagar Society, Behind ASD Towers, Old Padra Road, Vadodra - 390 015 Tel: 0265-356766.

For Gujarat State Fertilizers & Chemicals Limited
Sd/-
Nidhi Pillai
Place: Vadodra
Date: 25-05-2026
Company Secretary & Vice President (Legal)

OSWAL OVERSEAS LIMITED						
CIN No. : L74890DL1984PLC018268						
Regd. Office: 88A, Second Floor, Nandimor Estate, Taimoor Nagar, New Delhi 110005						
Phone No. - 011-41412555, Fax No. - 011- 26322484, E-mail:- cs@oswaloverseas.com, Website:- www.oswaloverseas.com						
EXTRACT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31.03.2026						
(Rs. in Lakhs)						
Sr. No.	Particulars	Quarter ended on 31.03.2026	Quarter ended on 31.03.2025	Quarter ended on 31.12.2025	Year ended on 31.03.2026	Year ended on 31.03.2025
		Audited	Audited	Unaudited	Audited	Audited
1.	Total income from operations (net)	221.25	2870.65	118.44	403.91	5782.63
2.	Net Profit/(Loss) from ordinary activities after tax (before Extraordinary Items)	-256.52	-210.39	-191.87	-918.74	-1239.20
3.	Net Profit/(Loss) for the period after tax (after Extraordinary Items)	-255.71	-209.92	-191.87	-919.96	-1238.43
4.	Other Comprehensive Income	2.30	0.45	0.01	4.97	2.19
5.	Net Profit/ Loss	-283.41	-209.43	-191.88	-912.03	-1236.24
6.	Equity Share Capital	646.11	646.11	646.11	646.11	646.11
7.	No. of Equity Shares of Rs. 5/- each	129.22	129.22	129.22	129.22	129.22
8.	Reserves (including Revaluation Reserve as shown in the Balance Sheet)	-	-	-	-4211.59	-3269.57
9.	Earnings Per Share (before extraordinary items) (face value of Rs. 10/- each)					
	Basic	-2.19	-1.62	-1.48	-7.06	-9.57
	Diluted	-2.19	-1.62	-1.48	-7.06	-9.57
Notes:						
1. The above is an extract of the detailed form of quarterly financial results filed with the stock exchanges under regulation 33 of the SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015. The full form of the quarterly and yearly financial results is available on the website of BSE Limited and the website of the company (www.oswaloverseas.com).						
2. The above information has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30 th May 2026.						
3. Super income is a seasonal industry wherein crushing normally takes place during the period between November and April, while sales are distributed throughout the year. The performance of the company varies from quarter to quarter.						
4. Pursuant to the provisions of section 115BBA of Income Tax Act 1961, as announced by the Taxation Laws (Amendment) Ordinance 2019 and promulgated as the Taxation Laws (Amendment) Act, 2019, enacted on 11 th December, 2019 with effect from 1 st April, 2019, domestic companies have an option to pay income tax at the concessional rate by forgoing certain exemptions / deductions, (the 'new tax regime').						
Based on the assessment of the possible impact of the new tax regime, the Company is decided to continue with existing tax structure till certain deductions are available and accumulated Minimum Alternate Tax (MAT) credit is substantially exhausted and thereafter to opt for new tax regime as stated above.						
Place : New Delhi Date : 30.05.2026					For Oswal Overseas Limited Sd/ Pratimajit Singh (Managing Director) CIN: 30313352	

NOTES:

1. The above is an extract of the detailed format of quarterly financial results filed with the stock exchanges under regulation 33 of the SEBI (Listing Obligations and Disclosures Regulation) Regulation, 2015. The full format of the quarterly and yearly financial results is available on the website of BSE Limited and the website of the company (www.oswaloverseas.com).

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30th May, 2026.

3. Sugar industry is a seasonal industry where crushing normally takes place during the period between November and April, while sales are distributed throughout the year. The financial results of the company are therefore seasonal in nature.

4. Pursuant to the provisions of section 115BBA of Income Tax Act 1961 as amended by the Taxation Laws (Amendment) Ordinance 2019 and promulgated as the Taxation Laws (Amendment) Act, 2019 enacted on 11th December, 2019 with effect from 1st April, 2021 domestic companies have an option to pay income tax at the concessional rate by foregoing certain exemptions/ deductions (the new tax regime) as specified in the said section.

5. Based on the assessment of the possible impact of the new tax regime, the Company has elected to continue with existing tax structure till certain deductions are available and accumulated Minimum Alternate Tax (MAT) credit is substantially exhausted and thereafter to opt for new tax regime as stated above.

For Oswal Overseas Limited
Sd/-
Paramjit Singh
(Managing Director)
CIN: 00313352

Place: New Delhi
Date: 30.05.2026

NOTICE AND JOINT ADVERTISEMENT FOR THE MEETING OF EQUITY SHAREHOLDERS, SECURED CREDITORS AND UNSECURED CREDITORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED
FORM NO. CAA-2
(PURSUANT TO SECTION 230(3) AND RULE 8 AND 7 OF COMPANIES (COMPROMISES, ARRANGEMENTS AND AMALGAMATIONS) RULES, 2016)
BEFORE THE NATIONAL COMPANY LAW TRIBUNAL, CHENNAI BENCH-I

AND

IN THE MATTER OF SECTIONS 230 TO 232 OF THE COMPANIES ACT, 2013 AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT, 2013 READ WITH COMPANIES (COMPROMISES, ARRANGEMENTS AND AMALGAMATIONS) RULES, 2016

AND

IN THE MATTER OF SCHEME OF AMALGAMATION

AMONGST

DR. AGARWAL'S EYE HOSPITAL LIMITED (APPLICANT COMPANY NO.1/ TRANSFEROR COMPANY)

AND

DR. AGARWAL'S HEALTH CARE LIMITED (APPLICANT COMPANY NO.2/ TRANSFEREE COMPANY)

AND

THEIR RESPECTIVE SHAREHOLDERS AND CREDITORS COMPANY APPLICATION (CAA) NO. 19/CHE/ 2026

DR. AGARWAL'S EYE HOSPITAL LIMITED
CIN: L85110TN1994PLC027366
(A Company registered under the Companies Act of 1956.
Having its registered office at 6th Floor, Monor Elementy, 1st Main Road, Austin Nagar, Alwarpet, Chennai, Tamil Nadu, India, 600 018.
Represented by Ms. Meenakshi Jayaraman, Company Secretary and Compliance Officer

Applciant Company No.1/ Transferor Company
Notice is hereby given that pursuant to the order dated May 05, 2026 ("Order"), the Hon'ble National Company Law Tribunal, Chennai Bench ("Hon'ble Tribunal") has directed the convening of the meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors of the Applicant Companies (hereinafter called as "Meetings") to be held for the purpose of considering, and if thought fit, approving with or without modification, the Scheme of Amalgamation amongst Dr. Agarwal's Eye Hospital Limited (Applicant Company No. 1/ Transferor Company) and Dr. Agarwal's Health Care Limited (Applicant Company No. 2/ Transferee Company) and their respective shareholders and creditors ("Scheme") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Act").

Pursuant to the Order and in accordance with the directions contained therein, further notice is hereby given that the Meetings will be convened and held as under:

Sr. No.	Name of the Company	Class of Meeting	Mode and Venue of Meeting	July 02, 2026	
				Time (IST)	Time (IST)
1.	Dr. Agarwal's Eye Hospital Limited (Applicant Company No. 1/ Transferor Company)	Equity Shareholders Secured Creditors Unsecured Creditors	Through Physical Mode at The Music Academy, T.T.K. Road, Chennai - 600 014.	09:00 A.M. 11:30 A.M.	09:00 A.M. 03:00 P.M.

The notice, together with the documents accompanying the same, of the Meetings has been sent to the Equity Shareholders of the Transferor Company whose names appear in the register of members / list of beneficial owners maintained by the depositories / Transferor Company, as mentioned below. Secured Creditors and Unsecured Creditors whose names are appearing in the records of the Transferor Company, as mentioned below:

Particulars of Meeting	Record date for Dispatch of Notice	Mode of Dispatch	
		Date	Time
Equity Shareholders of the Transferor Company	May 22, 2026	(i) Through electronic mode to the Equity Shareholders, Secured Creditors and Unsecured Creditors whose e-mail addresses are registered with NSDL/CDSL, or available with the Transferor Company as on the relevant record date; and	(ii) Through speed post, providing the web-link and Quick response code for accessing the Notice and related documents hosted on the website of the Company, to those whose e-mail addresses are not so registered or available.

Copies of the Scheme, the statement under Sections 230 and 232 read with Section 102 of the Act and Rule 8 of the CAA Rules, and related documents are available on the website of the Transferor Company at <https://dragarwal.com/cn/dr-agarwal-eyes-hospital-ltd-convened-meeting-documents>, as well as on the websites of BSE Limited and NSDL. Physical copies may also be obtained free of cost by writing to sec@dragarwal.com. Alternatively, the documents can also be accessed by scanning the QR code.

Persons entitled to attend and vote at the meeting of the Equity Shareholders, Secured Creditors and Unsecured Creditors of the Transferor Company may cast their votes through remote e-voting prior to the meeting or through polling paper / i-voting at the meeting, in accordance with the instructions contained in the Notice. Such persons may attend and vote either in person or through proxy or authorized representative, as applicable, provided that the duly completed proxy forms and authorization letters are deposited at the respective registered offices of the Transferor Company or emailed to investor@dragarwal.com at least 48 hours before the meeting. Attendees are requested to bring the duly signed attendance slip annexed to the Notice.

Equity Shareholders, Secured Creditors and Unsecured Creditors who have not attended through remote e-voting may vote electronically at the meeting in the manner provided in the Notice, whereas those who have already voted through remote e-voting may attend the meeting but shall not vote again. Only Equity Shareholders whose names appear in the register of members or beneficial owners as on the cut-off date shall be entitled to attend and vote at the meeting, and their voting rights shall be proportionate to their shareholding in the paid-up equity share capital of the Transferor Company as on such date. Voting rights of the Creditors shall be proportionate to the debt due to them as on the cut-off date. Furthermore, equity shareholders and creditors are requested to carefully read the detailed instructions on voting either through NSDL, e-voting facility or through polling papers and i-voting facility or via voting papers.

The Hon'ble NCLT has appointed Shri Kamal Jee Anra as the Chairperson and Shri Shyam Anand V. as the Scrutinizer of the aforesaid meetings of the Transferor Company. The above-mentioned Scheme, if approved in the Meetings, will be subject to the subsequent approval of the Hon'ble NCLT and such approvals, permissions and sanctions of regulatory or other authorities, as may be necessary and other conditions precedent as contemplated in the Scheme.

The cut-off date for voting (including remote e-voting, through polling papers and e-voting during the meeting) and time period for the voting of the aforesaid meeting is as under:

Particulars	Cut-off date for e-voting	Remote e-voting start date and time	Remote e-voting end date and time
Equity Shareholders of the Transferor Company	June 03, 2026	Sunday, June 07, 2026 at 09:00 A.M. (IST)	Wednesday, July 01, 2026 at 05:00 P.M. (IST)
Secured Creditors of the Transferor Company	December 31, 2025	09:00 A.M. (IST)	05:00 P.M. (IST)
Unsecured Creditors of the Transferor Company	December 31, 2025	09:00 A.M. (IST)	05:00 P.M. (IST)

The remote e-voting will not be allowed beyond the aforesaid date and time and the remote e-voting module shall be forthwith disabled by NSDL upon expiry of aforesaid period.

Detailed instructions regarding registration / updation of e-mail addresses, receipt of the Notice, login credentials, participation in e-voting and the process for shareholders acquiring shares after dispatch of the Notice are provided in the Notice. The voting results along with the Scrutinizer's Report shall be made available on the websites of the Transferor Company, NSDL, and shall also be intimated to the relevant stock exchanges in accordance with applicable law.

Equity Shareholders, Secured Creditors and Unsecured Creditors of the Transferor Company are requested to note the following contact details for addressing e-voting related queries / grievances, if any to NSDL or refer to the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders on: www.evoting.nsdl.com; Email: evoting@nsdl.com; Call on: 022-4886 7000 and 022-2489 7000.

For and on behalf of Dr. Agarwal's Eye Hospital Limited
Sd/-
Ms. Meenakshi Jayaraman
Company Secretary and Compliance Officer

Place: Chennai
Date: June 01, 2026

Nectar Lifesciences Limited				
Regd. Office: Shop No. 5, SL Enclave, Behind Sahi HP Gas Agency, Barwala Road, Dera Bassi, Distt. S.A.S. Nagar, Punjab 140507, Tel. +91-0172-507200, 5001687, Email : cs@nectarlifesciences.com, Website : www.nectarlifesciences.com, [CIN: L21000PB1995PLC016664]				
Extract of Audited Financial Results for the Quarter and the year ended 31.03.2026				
Sr. Particulars	Standalone		Consolidated	
	Quarter ended 31-03-2026	Year ended 31-03-2026	Quarter ended 31-03-2026	Year ended 31-03-2026
1. Total income from continuing operations	129.97	0.63	201.05	128.97
2. Net Profit/(Loss), before tax and before Exceptional items from continuing operations	(5,691.96)	(16.31)	(8,786.99)	(5,692.86)
3. Net Profit/(Loss), before tax after Exceptional items from continuing operations	(5,691.96)	(16.31)	(8,786.99)	(5,692.86)
4. Net Profit/(Loss), before tax and after Exceptional items from continuing operations	(3,720.60)	(10.60)	(5,734.11)	(3,721.22)
5. Net Profit/(Loss), before tax and before Exceptional items from discontinued operations	(7,320.58)	(18,750.17)	(53,765.51)	(7,320.58)
6. Net Profit/(Loss), before tax after Exceptional items from discontinued operations	-	-	16,337.32	-
7. Net Profit/(Loss), after tax and after Exceptional items from discontinued operations	(3,071.20)	(12,998.30)	(3,071.20)	(12,998.30)
8. Total Profit/(Loss) for the period from continuing and discontinued operations	(6,791.80)	(13,008.90)	(29,288.48)	(6,792.42)
9. Other Comprehensive Income	7.92	53.98	7.92	53.98
10. Total Comprehensive Income (after tax)	(6,783.88)	(12,954.92)	(29,280.56)	(6,784.49)
11. Paid up Share Capital (face value of ₹1/- each)	1,942.61	2,242.61	1,942.61	2,242.61
12. Other Equity excluding Revaluation Reserve from Audited Balance Sheet	56,288.19	93,368.74	56,288.19	93,368.74
13. No. of weighted average shares (in Numbers)	20,09,27,637	22,42,60,370	20,09,27,637	22,42,60,370
14. Earnings per Share (face value of ₹1/- each)	(1.85)	-	(2.85)	(1.85)
a. Basic - Continuing operations	(1.85)	-	(2.85)	(1.85)
b. Diluted - Continuing operations	(1.85)	-	(2.85)	(1.85)
c. Basic - Discontinued operations	(1.53)	(5.80)	(11.72)	(1.53)
d. Diluted - Discontinued operations	(1.53)	(5.80)	(11.72)	(1.53)
e. Basic - Continuing and Discontinued operations	(3.38)	(5.80)	(14.58)	(3.38)
f. Diluted - Continuing and Discontinued operations	(3.38)	(5.80)	(14.58)	(3.38)

NOTE: 1. The above is an extract of the detailed format of Quarterly and Year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The full format of the financial results (including standalone results) are available on the company's website at <https://www.nectarlifesciences.com/about-us> (which can also be downloaded by scanning the QR code given below) and on the website of the Stock Exchanges at www.sebiindia.com and www.nsdl.com. The Board of Directors hereby declare that audit reports do not have any modified opinion. 2. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.

By Order of the Board of Directors of Nectar Lifesciences Limited
(Sd/-)
Chairman & Managing Director

Dated: 30-05-2026
Place: Chandigarh

NOTICE AND JOINT ADVERTISEMENT FOR THE MEETING OF EQUITY SHAREHOLDERS, SECURED CREDITORS AND UNSECURED CREDITORS OF DR. AGARWAL'S HEALTH CARE LIMITED
FORM NO. CAA-2
(PURSUANT TO SECTION 230(3) AND RULE 8 AND 7 OF COMPANIES (COMPROMISES, ARRANGEMENTS AND AMALGAMATIONS) RULES, 2016)
BEFORE THE NATIONAL COMPANY LAW TRIBUNAL, CHENNAI BENCH-I

AND

IN THE MATTER OF SECTIONS 230 TO 232 OF THE COMPANIES ACT, 2013 AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT, 2013 READ WITH COMPANIES (COMPROMISES, ARRANGEMENTS AND AMALGAMATIONS) RULES, 2016

AND

IN THE MATTER OF SCHEME OF AMALGAMATION

AMONGST

DR. AGARWAL'S EYE HOSPITAL LIMITED (APPLICANT COMPANY NO.1/ TRANSFEROR COMPANY)

AND

DR. AGARWAL'S HEALTH CARE LIMITED (APPLICANT COMPANY NO.2/ TRANSFEREE COMPANY)

AND

THEIR RESPECTIVE SHAREHOLDERS AND CREDITORS COMPANY APPLICATION (CAA) NO. 19/CHE/ 2026

DR. AGARWAL'S HEALTH CARE LIMITED
CIN: L85110TN1994PLC027366
(A Company registered under the Companies Act of 1956.
Having its registered office at 6th Floor, Monor Elementy, 1st Main Road, Austin Nagar, Alwarpet, Chennai, Tamil Nadu, India, 600 018.
Represented by Mr. Thirukantharun Arumugam, Company Secretary and Compliance Officer

Applciant Company No.2/ Transferee Company
Notice is hereby given that pursuant to the order dated May 05, 2026 ("Order"), the Hon'ble National Company Law Tribunal, Chennai Bench ("Hon'ble Tribunal") has directed the convening of the meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors of the Applicant Companies (hereinafter called as "Meetings") to be held for the purpose of considering, and if thought fit, approving with or without modification, the Scheme of Amalgamation amongst Dr. Agarwal's Eye Hospital Limited (Applicant Company No. 1/ Transferor Company) and Dr. Agarwal's Health Care Limited (Applicant Company No. 2/ Transferee Company) and their respective shareholders and creditors ("Scheme") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Act").

Pursuant to the Order and in accordance with the directions contained therein, further notice is hereby given that the Meetings will be convened and held as under:

approving with or without modification, the Scheme of Amalgamation amongst Dr Agarwal's Eye Hospital Limited (Applicant Company No. 1, Transferor Company) and Dr Agarwal's Health Care Limited (Applicant Company No. 2, Transferee Company) and the respective shareholders and creditors ("**Scheme**") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Act").

Pursuant to the Order and in accordance with the directions contained therein, further notice is hereby given that the Meetings will be